Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Hungary.
Department of Physiology, Anatomy, and Genetics, University of Oxford, United Kingdom; Department of Computer Science, University of Oxford, United Kingdom.
J Mol Cell Cardiol. 2021 Apr;153:111-122. doi: 10.1016/j.yjmcc.2020.12.015. Epub 2020 Dec 28.
Repolarization alternans, a periodic oscillation of long-short action potential duration, is an important source of arrhythmogenic substrate, although the mechanisms driving it are insufficiently understood. Despite its relevance as an arrhythmia precursor, there are no successful therapies able to target it specifically. We hypothesized that blockade of the sodium‑calcium exchanger (NCX) could inhibit alternans. The effects of the selective NCX blocker ORM-10962 were evaluated on action potentials measured with microelectrodes from canine papillary muscle preparations, and calcium transients measured using Fluo4-AM from isolated ventricular myocytes paced to evoke alternans. Computer simulations were used to obtain insight into the drug's mechanisms of action. ORM-10962 attenuated cardiac alternans, both in action potential duration and calcium transient amplitude. Three morphological types of alternans were observed, with differential response to ORM-10962 with regards to APD alternans attenuation. Analysis of APD restitution indicates that calcium oscillations underlie alternans formation. Furthermore, ORM-10962 did not markedly alter APD restitution, but increased post-repolarization refractoriness, which may be mediated by indirectly reduced L-type calcium current. Computer simulations reproduced alternans attenuation via ORM-10962, suggesting that it is acts by reducing sarcoplasmic reticulum release refractoriness. This results from the ORM-10962-induced sodium‑calcium exchanger block accompanied by an indirect reduction in L-type calcium current. Using a computer model of a heart failure cell, we furthermore demonstrate that the anti-alternans effect holds also for this disease, in which the risk of alternans is elevated. Targeting NCX may therefore be a useful anti-arrhythmic strategy to specifically prevent calcium driven alternans.
复极电交替,即长短动作电位时程的周期性振荡,是致心律失常基质的一个重要来源,尽管其驱动机制尚未完全明了。尽管它是心律失常的前期表现,但目前尚无成功的治疗方法能够专门针对它。我们假设钠钙交换体(NCX)阻断可能会抑制电交替。我们评估了选择性 NCX 阻断剂 ORM-10962 对犬乳头肌标本微电极测量的动作电位和 Fluo4-AM 测量的分离心室肌细胞钙瞬变的影响,这些细胞通过起搏引发电交替。计算机模拟用于深入了解药物的作用机制。ORM-10962 减弱了心脏电交替,包括动作电位时程和钙瞬变幅度。观察到三种形态的电交替,对 ORM-10962 的反应在 APD 电交替衰减方面存在差异。APD 复极恢复分析表明,钙振荡是电交替形成的基础。此外,ORM-10962 并未明显改变 APD 复极恢复,但增加了复极后不应期,这可能是间接减少 L 型钙电流介导的。计算机模拟通过 ORM-10962 再现了电交替衰减,表明其通过减少肌浆网释放不应期来发挥作用。这是由于 ORM-10962 诱导的钠钙交换体阻断伴随着间接减少 L 型钙电流。我们还使用心力衰竭细胞的计算机模型证明,这种抗电交替效应也适用于该病,该病的电交替风险升高。因此,靶向 NCX 可能是一种有用的抗心律失常策略,可专门预防钙驱动的电交替。